Pharmacological modulation of the leukotriene pathway in allergic airway disease

Drug Discovery Today

Volumn 12, Issue 9-10, 2007, Pages 404-412

  Montuschi, Paolo ^a   Sala, Angelo ^b   Dahlén, Sven Erik ^c   Folco, Giancarlo ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLERGEN; ARACHIDONATE 5 LIPOXYGENASE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; FLUTICASONE; G PROTEIN COUPLED RECEPTOR; GLUCOCORTICOID; LEUKOTRIENE; LEUKOTRIENE A4; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PEPTIDOLEUKOTRIENE; PEPTIDOLEUKOTRIENE RECEPTOR 1 ANTAGONIST; PHOSPHOLIPASE A2; PRANLUKAST; SALMETEROL; UNCLASSIFIED DRUG; ZAFIRLUKAST; ZILEUTON;

AIRWAY; ALLERGIC ASTHMA; ALLERGIC RHINITIS; APOPTOSIS; ASTHMA; B LYMPHOCYTE; BASOPHIL; BIOACCUMULATION; BRONCHOSPASM; CD8+ T LYMPHOCYTE; CELL TYPE; COMBINATION CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MARKETING; ENDOTHELIUM CELL; EOSINOPHIL; EPITHELIUM CELL; ERYTHROCYTE; EXERCISE; FIBROBLAST; FORCED EXPIRATORY VOLUME; HEMATOPOIETIC STEM CELL; HUMAN; MACROPHAGE; MAST CELL; MONOCYTE; MONOTHERAPY; MUCUS; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; REVIEW; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; THROMBOCYTE; TREATMENT DURATION;

ASTHMA; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; SIGNAL TRANSDUCTION;

EID: 34247392438     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.03.004     Document Type: Review

References (69)

1. Bochner B.S., and Busse W. Allergy and asthma. J. Allergy Clin. Immunol. 115 (2005) 953-959
2. O'Byrne P.M. Cytokines or their antagonists for the treatment of asthma. Chest 130 (2006) 244-250
3. Dahlen S.E. Treatment of asthma with antileukotrienes: first line or last resort therapy?. Eur. J. Pharmacol. 533 (2006) 40-56
4. Busse W., and Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 127 (2005) 1312-1326
5. Peters-Golden M., et al. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin. Exp. Allergy 36 (2006) 689-703
6. Folco G., and Murphy R.C. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol. Rev. 58 (2006) 1-14
7. de Graaf-in t'Veld C., et al. Relationship between nasal hyperreactivity, mediators and eosinophils in patients with perennial allergic rhinitis and controls. Clin. Exp. Allergy 26 (1996) 903-908
8. Wang D., et al. Efficacy and onset of action of fluticasone propionate aqueous nasal spray on nasal symptoms, eosinophil count, and mediator release after nasal allergen challenge in patients with seasonal allergic rhinitis. Allergy 53 (1998) 375-382
9. Shirasaki H., et al. Expression and localization of the cysteinyl leukotriene 1 receptor in human nasal mucosa. Clin. Exp. Allergy 32 (2002) 1007-1012
10. Dahlen B., et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am. J. Resp. Crit. Care Med. 157 (1998) 1187-1194
11. 4 and prostanoids in asthmatic children. J. Allergy Clin. Immunol. 118 (2006) 347-353
12. Holgate S.T., et al. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J. Allergy Clin. Immunol. 111 (2003) S18-S36
13. 1 receptor. Nature 399 (1999) 789-793
14. 1R. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 11589-11593
15. Figueroa D.J., et al. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am. J. Resp. Crit. Care Med. 163 (2001) 226-233
16. Leigh R., et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am. J. Resp. Crit. Care Med. 166 (2002) 1212-1217
17. Leff J.A., et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N. Engl. J. Med. 339 (1998) 147-152
18. Dahlen S.E., et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am. J. Resp. Crit. Care Med. 165 (2002) 9-14
19. Price D.B., et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 58 (2003) 211-216
20. Busse W., et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J. Allergy Clin. Immunol. 107 (2001) 461-468
21. 1 receptor blockade. Am. J. Resp. Crit. Care Med. 173 (2006) 718-728
22. Kelly M.M., et al. Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest 130 (2006) 741-753
23. Wenzel S.E., et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am. J. Resp. Crit. Care Med. 156 (1997) 737-743
24. Montuschi P., and Barnes P.J. Exhaled leukotrienes and prostaglandins in asthma. J. Allergy Clin. Immunol. 109 (2002) 615-620
25. Mondino C., et al. Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children. J. Allergy Clin. Immunol. 114 (2004) 761-767
26. In: Montuschi P. (Ed). New Perspectives in Monitoring Lung Inflammation: Analysis of Exhaled Breath Condensate (2005), CRC Press
27. 4 receptor antagonist, LY293111, on allergen-induced responses in asthma. Thorax 51 (1996) 1178-1184
28. James A.J., et al. Human bronchial fibroblasts express the 5-lipoxygenase pathway. Resp. Res. 7 (2006) 102
29. Ciana P., et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 25 (2006) 4615-4627
30. Gauvreau G.M., et al. Expression of functional cysteinyl leukotriene receptors by human basophils. J. Allergy Clin. Immunol. 116 (2005) 80-87
31. Di Gennaro A., et al. Cysteinyl-leukotrienes receptor activation in brain inflammatory reactions and cerebral edema formation: a role for transcellular biosynthesis of cysteinyl-leukotrienes. FASEB J. 18 (2004) 842-844
32. Figueroa D.J., et al. Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis. Clin. Exp. Allergy 33 (2003) 1380-1388
33. Fujii M., et al. Interferon-γ up-regulates expression of cysteinyl leukotriene type 2 receptors on eosinophils in asthmatic patients. Chest 128 (2005) 3148-3155
34. Naik S., et al. Regulation of cysteinyl leukotriene type 1 receptor internalization and signaling. J. Biol. Chem. 280 (2005) 8722-8732
35. 2: expression and function in human and murine mast cells. J. Immunol. 177 (2006) 339-3447
36. 4: novel interactions in the persistence and progression of asthma. J. Allergy Clin. Immunol. 117 (2006) 577-582
37. 4 and methacholine on sputum cell differentials in asthma. Am. J. Resp. Crit. Care Med. 155 (1997) 1247-1253
38. 2 cell-dependent pulmonary inflammation. J. Immunol. 176 (2006) 4440-4448
39. Fischer A.R., et al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am. J. Resp. Crit. Care Med. 152 (1995) 1203-1207
40. Riccioni G., et al. Comparison of montelukast and budesonide on bronchial reactivity in subjects with mild-moderate persistent asthma. Pulm. Pharmacol. Ther. 16 (2003) 111-114
41. Berges-Gimeno M.P., et al. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin. Exp. Allergy 32 (2002) 1491-1496
42. Kumlin M. Measurement of leukotrienes in humans. Am. J. Resp. Crit. Care Med. 161 (2000) S102-S106
43. Pavord I.D., et al. Induced sputum eicosanoid concentrations in asthma. Am. J. Resp. Crit. Care Med. 160 (1999) 1905-1909
44. Wenzel S.E., et al. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am. J. Resp. Crit. Care Med. 152 (1995) 897-905
45. 4 excretion (hyperleukotrienuria): involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J. Allergy Clin. Immunol. 113 (2004) 277-283
46. 4 levels in acute asthma: correlation with airflow limitation. Thorax 59 (2004) 100-104
47. Anon. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur. Resp. J. (2003) 470-477
48. 4 in exhaled breath condensate. Eur. Resp. J. 28 (2006) 1229-1235
49. Horvath I., et al. ATS/ERS Task Force on exhaled breath condensate. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur. Resp. J. 26 (2005) 523-548
50. Plewako H., et al. Increased expression of lipoxygenase enzymes during pollen season in nasal biopsies of pollen-allergic patients. Allergy 61 (2006) 725-730
51. 4 levels. Allergy Asthma Proc. 17 (1996) 93-99
52. Camargo Jr. C.A., et al. A randomized controlled trial of intravenous montelukast in acute asthma. Am. J. Resp. Crit. Care Med. 167 (2003) 528-533
53. Roquet A., et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am. J. Resp. Crit. Care Med. 155 (1997) 1856-1863
54. Phipatanakul W., et al. The efficacy of montelukast in the treatment of cat allergen-induced asthma in children. J. Allergy Clin. Immunol. 109 (2002) 794-799
55. Pearlman D.S., et al. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann. Allergy Asthma Immunol. 97 (2006) 98-104
56. Villaran C., et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/salmeterol exercise study group. J. Allergy Clin. Immunol. 104 (1999) 547-553
57. Melo R.E., et al. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late-phase responses. J. Allergy Clin. Immunol. 111 (2003) 301-307
58. Szefler S.J., et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J. Allergy Clin. Immunol. 115 (2005) 233-242
59. Vaquerizo M.J., et al. CASIOPEA (Capacidad de Singulair Oral en la Prevencion de Exacerbaciones Asmaticas) Study Group. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 58 (2003) 204-210
60. Bjermer L., et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 327 (2003) 891
61. 2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst. Rev. 4 (2006) CD003137
62. Lofdahl C.G., et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 319 (1999) 87-90
63. 4 is resistant to inhaled fluticasone propionate. J. Allergy Clin. Immunol. 118 (2006) 78-83
64. Ward C., et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 57 (2002) 309-316
65. Hoshino M., et al. Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J. Allergy Clin. Immunol. 103 (1999) 1054-1061
66. Bisgaard H., et al. Intermittent inhaled corticosteroids in infants with episodic wheezing. N. Engl. J. Med. 354 (2006) 1998-2005
67. Meltzer E.O., et al. Montelukast effectively treats the nighttime impact of seasonal allergic rhinitis. Am. J. Rhinol. 19 (2005) 591-598
68. Patel P., et al. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann. Allergy Asthma Immunol. 95 (2005) 551-557
69. Price D.B., et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 61 (2006) 737-742